Eli Lilly & Co Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
30.2%projected annual EPS growth
Analyst Coverage
28analysts covering
FY Revenue (est.)
$88.2Bnext fiscal year
FY EPS (est.)
$36.73next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Next Earnings Release | 29 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly revenue (USD billions) Quarterly23.0
Quarterly Mounjaro revenue (USD billions) Quarterly9.9
Watch Items
- Full-year revenue performance versus the lower bound of Lilly's updated 2026 guidance
- Net-pricing pressure that could offset cardiometabolic volume growth
Research as of 29 Aug 2026